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Abstract. Schistosomiasis remains one of the most prevalent parasitic diseases worldwide and the infection is
frequently found in travelers and migrants. The European Network for Tropical Medicine and Travel Health conducted a
sentinel surveillance study on imported schistosomiasis between 1997 and 2010. This report summarizes epidemio-
logical and clinical data from 1,465 cases of imported schistosomiasis. Direct pathogen detection and serology were the
main diagnostic tools applied. Of these, 486 (33%) cases were identified among European travelers, 231 (16%) among
long-term expatriates, and 748 (51%) among non-European immigrants. Overall, only 18.6% of travelers had received
pretravel advice; 95% of infections were acquired in the African region. On species level, Schistosoma mansoni was
identified in 570 (39%) and Schistosoma haematobium in 318 (22%) cases; 57.5% of patients were symptomatic. Acute
symptoms were reported in 27% of patients leading to earlier presentation within 3 months. Praziquantel was used in all
patients to treat schistosomiasis. Many infections were detected in asymptomatic patients. In 47.4% of asymptomatic
patients infection was detected by microscopy and in 39% by serology or antigen testing. Schistosomiasis remains a
frequent infection in travelers and migrants to Europe. Travelers should be made aware of the risk of schistosomiasis
infection when traveling to sub-Saharan Africa. Posttravel consultations particularly for returning expatriates are useful
given the high potential for detecting asymptomatic infections.
INTRODUCTION
Schistosomiasis is one of the most prevalent parasitic dis-
eases worldwide, affecting > 200 million people in 78 coun-
tries. It is estimated that around 120 million individuals are
symptomatic and 20 million have severe disease.1,2 Accord-
ing to World Health Organization estimates, over 260 million
people required treatment of schistosomiasis in the year 2013
of whom 92% live in the African region.3
Patients born in endemic countries acquire the infection
during childhood andmay develop a chronic disease because
of continuous reinfection through freshwater contact. How-
ever, schistosomiasis is also an important travel-associated
infection and frequently seen among returnees from endemic
areas.4 Symptoms in travelers differ from symptoms in
chronically infected individuals. Travelers may present with
symptoms of the acute phase of infection which is also known
as Katayama syndrome, a nonspecific febrile illness with
typically high eosinophilia and a skin rash, usually occurring in
the first 3 months after infection. Swimmer’s itch may also be
reported by travelers several days after freshwater contact.
Initially, serology can still be negative and no eggs are found in
urine or stool. In this acute phase of infection, diagnosis is very
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difficult5 despite recent advances in diagnostic methods such
as polymerase chain reaction (PCR) or antigen testing.6,7
Symptoms of chronic disease occur several months or years
after travel or leaving endemic areas and can be mistaken for
other diseases, especially outside endemic countries.
Schistosomiasis is considered aneglected tropical disease.
In Europe, it is diagnosed and treated in referral centers for
tropical medicine. International travel and migration is
increasing8,9 and there is also a potential for reemergence in
the Mediterranean areas of Europe.10,11 The European Net-
work for Tropical Medicine and Travel Health (TropNet, http:
//www.tropnet.eu), a network of clinical referral centers for
tropical and travel medicine Europe, conducted a sentinel
surveillance study of imported tropical diseases from 1997 to
2010. We present demographic, clinical, and geographic
features of imported schistosomiasis from this large dataset.
METHODS
TropNet collected demographic and clinical data from
patients with travel or migration history seen at one of the 38
member sites in 16 countries across Europe between the
years 1997 and 2010. Patients who presented to one of
these participating centers and in whom a diagnosis of
schistosomiasis was established were reported using a
standardized questionnaire in either paper-based or elec-
tronic format. Data were anonymized before transfer to the
central database.
Theprimary objective of this analysiswas toprovide clinical,
epidemiological, and geographic information on schistoso-
miasis imported to Europe with regard to patient origin and
type of travel as well as an analysis of possible risk factors
associated with infection.
Thespecific final diagnosis of schistosomiasiswas reported
by the individual TropNet center via the respective In-
ternational Classification of Diseases (ICD)-10 code for
schistosomiasis (ICD-10 B65 + subgroup). Furthermore,
centers were required to classify their final diagnosis as
“confirmed,” “probable,” or “suspected” on the basis of the
following definitions: cases were reported as “confirmed” in
case of clinical symptoms with positive microscopic egg de-
tection in urine, semen, stool, or positive biopsy material and
PCR. A “probable” definition was declared in case of typical
clinical symptoms together with a positive serology for IgG or
IgM or antigen detection (via indirect hemagglutination, fluo-
rescence antibody test or enzyme-linked immunosorbent
assay). Cases classified as “suspected” (evident clinical signs
of schistosomiasis together with a typical travel history aswell
as cases with any concomitant acute infection) were also re-
ported but excluded from further analysis. In addition, the
questionnaire allowed to specify one diagnostic method used
to establish the diagnosis.
Cases were classified according to permanent residence/
origin, reason for travel, and symptoms of acute or chronic
schistosomiasis. Data on permanent residence and origin
were used to classify travelers as 1) immigrants or refugees
from endemic countries living in Europe and visitors to Europe
from endemic areas (termed as “non-Europeans”), 2) individ-
uals fromEurope visiting endemic areas for a definedperiod of
time (termed as “Europeans”), and 3) individuals from Europe
living and working in endemic areas for a prolonged period of
time of over 1 year (termed as “expatriates”).
Reasons for travel included 1) business trip, 2) migration, 3)
military service, 4) missionary/humanitarian, 5) scientific, 6)
tourism, and7) visiting friends and relatives (VFR). Thedates of
return from travel or migration were recorded as well as the
time point of presentation; presentation within 3 months was
classified as early presentation.
Symptoms were reported as 1) fever, 2) fatigue, 3) skin
symptoms, 4) respiratory symptoms, 5) headache, 6) lymph-
adenopathy, 7) musculoskeletal symptoms, 8) diarrhea, 9)
vomiting, 10) otolaryngologic symptoms (eyes, nose, throat),
and 11) neurological symptoms. Multiple entries per patient
were allowed. Further symptoms or conditions were report-
able by text. To differentiate between acute or chronic pre-
sentation, we assigned the reported symptoms to twogroups:
1) acute/subacute schistosomiasis was assumed if patients
presented with fever, fatigue, skin symptoms, respiratory
symptoms, headache, musculoskeletal symptoms, otolar-
yngologic symptoms, night sweats, vomiting, diarrhea, neu-
rological symptoms, and eosinophilia together with fever
or respiratory symptoms. 2) Chronic schistosomiasis was
assumed for cases presenting with weight loss, signs of
hepatosplenic disease, liver disease, melena, hematuria,
hematospermia, or hematochezia.
Statistical analysis was carried out using JMP (JMP 11.0,
SAS Institute Inc, NC). Categorical data were analyzed using
the χ2 test and Fisher’s exact test, as appropriate, at an ad-
justed two-sided significance level of α < 0.01 due to multiple
comparisons. Continuous data were analyzed using the
Mann–Whitney U test.
The studywas approved by the ethics committee of Charité
University Hospital Berlin. Ethical clearance for transfer of
anonymized patient data was sought at participating TropNet
centers according to local regulations.
RESULTS
Patient classification and demographic data. The data-
base contained 1,587 cases with a diagnosis of schistoso-
miasis over 14 years. After exclusion of suspected cases (N =
35), caseswith inconsistent data (N = 72) and caseswithmore
than one diagnosis of acute infection (N = 15), 1,465 cases
remained available for analysis. Of these, 61.3% of cases
(899/1,465) were reported as confirmed and 38.7% of cases
(566/1,465) were reported as probable. Demographic data are
given in Table 1. Of these, 486 (33%) cases were diagnosed
among Europeans, 231 (16%) among expatriates, and 748
(51%) among non-Europeans.
Time of presentation. During the study period of 14 years, a
median of 120.5 patients (IQR25 68.25, IQR75 134.5 patients)
presented each year. The overall number of presenting patients
was stable without any significant trend. Data on the time to
presentation toahealth-carecenterafter leavingschistosomiasis
endemic areas are given in Table 2: 53.2%of patients presented
within 3 months and 46.8% in > 3months after leaving endemic
areas. Patients who had obtained pretravel advice presented
more likely within 3 months (P < 0.0001). Europeans and expa-
triates presented earlier than non-Europeans.
Species of schistosomiasis. Species information was
available in 898/1,465 (61%) of cases. Urogenital schistoso-
miasis due to Schistosoma haematobium was diagnosed in
22% of cases (318/1,465). Among these, 63.8% (203/318)
were found in non-Europeans, 4.7% (15/318) among
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expatriates, and 31.5% (100/318) among Europeans. In-
testinal schistosomiasis due to Schistosoma mansoni was
diagnosed in 39% of cases (570/1,465). Among those, 61%
(348/570) were found among non-Europeans, 23% (131/570)
among expatriates, and 16% (91/570) amongEuropeans. Five
cases of Schistosoma japonicum were identified (two non-
Europeans, two expatriates, and one European), one con-
firmed infection with Schistosoma intercalatum (an immigrant
from Cameroon), and four cases of Schistosoma mekongi (all
among European tourists returning from travels from south-
east Asia). Double infections were reported in seven cases;
these patients were all infected with S. mansoni and
S. haematobium, both species were detected viamicroscopy.
Of 1,465cases, 567were not further classifiedor reportedona
species level (39%).
Place of infection and Schistosoma species. Most in-
fections were acquired in Africa (N = 1,405, 95%) followed by
South America (N = 21, 1.4%) and southeast Asia (N = 21,
1.4%). Table 3 shows the regions of infection. Figure 1 illus-
trates the geographical distribution of the origin of all
schistosomiasis infections by patient type: 99% of infections
with S. haematobium were acquired in Africa (315/318 cases)
(Figure 2); 67% (N = 216) of cases were imported from west
Africa with most cases originating fromMali (N = 86), Senegal
(N = 41), and Ghana (N = 26); and 23% (N = 74) of cases were
acquired in east Africa, wheremost cases were imported from
Malawi (N = 34) mainly by tourist travelers. Intestinal schisto-
somiasis due toS.mansoniwasprimarily imported fromAfrica
in 96% of cases (547/570), followed by South America with
2.6% of cases (15/570) and the Caribbean/Central America
with 0.7% of cases (4/570). On the African continent, most
infections occurred in west Africa (36%) followed by Central
Africa (28%) and east Africa (27%) (Figure 3).
In 188 cases (all species), information on the exact places of
infectionwas given: the fivemost frequently namedwere Lake
Victoria (N = 38), Lake Malawi (N = 37), and lakes near
Lubumbashi (DemocraticRepublic of theCongo) (N=23), river
Nile (N = 19), and Lake Kivu (N = 19).
Symptoms of schistosomiasis. Table 4 gives an overview
of reported symptoms: 57.5% of patients presented with
TABLE 2
Time to presentation for all patients
Time to presentation < 3 months Time to presentation > 3 months
Pearson χ2 testN = 713 (53.2%)* N = 628 (46.8%)*
Patient origin
European 255 (57%) 192 (43%) P < 0.0001
Expatriate 177 (81.9%) 39 (18.1%)
Non-European 281 (41.5%) 397 (58.5%)
Purpose of travel†
Tourist 183 (59.8%) 123 (40.2%) P < 0.0001
VFR 83 (52.2%) 76 (47.8%)
Migration 162 (35.2%) 298 (64.8%)
Missionary/humanitarian 110 (69.2%) 49 (30.2%)
Pretravel advice obtained
Yes 173 (68.4%) 80 (31.6%) P < 0.0001
VFR = visiting friends and relatives.
* Information on 246 cases was not given.
† Not all categories listed.
TABLE 1
Demographic data by patient type
Total N = 1,465 European N = 486 (33%) Expatriate N = 231 (16%) Non-European N = 748 (51%) Pearson χ2 test
Sex P = 0.0014
Male 983 (67.1%) 299 (61.5%) 153 (66.2%) 531 (71.0%)
Female 478 (32.6%) 187 (38.5%) 78 (33.8%) 213 (28.5%)
No data 4 (0.3%) 0 (0.0%) 0 (0.0%) 4 (0.5%)
Age P = 0.0001
IQR 25 22 24 14.25 20.75
Median 29 30 35 28
IQR 75 38 39 45.75 36
Pretravel advice P < 0.0001
Yes 273 (18.6%) 201 (41.4%) 65 (28.1%) 7 (0.9%)
No 298 (20.4%) 60 (12.3%) 15 (6.5%) 223 (29.8%)
Unknown 894 (61.0%) 225 (46.3%) 151 (65.4%) 518 (69.3%)
Purpose of travel* P < 0.0001
Migration 486 (33.2%) 1 (0.2%) 1 (0.4%) 484 (64.7%)
Missionary/humanitarian 171 (11.7%) 49 (10.1%) 106 (45.9%) 16 (2.1%)
Tourist 343 (23.4%) 326 (67.1%) 4 (1.7%) 13 (1.7%)
Visiting friends/relatives 191 (13.0%) 11 (2.3%) 3 (1.3%) 177 (23.7%)
Symptoms P = 0.0001
Yes 842 (57.5%) 294 (60.5%) 87 (37.7%) 461 (61.6%)
Asymptomatic/not reported 623 (42.5%) 192 (39.5%) 144 (62.3%) 287 (38.4%)
IQR = interquartile range.
* Not all categories listed.
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clinical symptoms. Acute/subacute presentation of schisto-
somiasis, as defined earlier, was significantly more frequent in
European travelers (N = 167, 34%) than in expatriates (N = 53,
23%; P = 0.0019) or non-Europeans (N = 171, 23%; P <
0.0001). Fever and acute/subacute symptoms in general were
associatedwith early presentationwithin 3months (P<0.0001
and P = 0.008, respectively).
In the subgroup of patientswith urogenital schistosomiasis,
non-Europeans presented in 61% (N = 123) of cases with
chronic or urogenital symptoms, which was significantly
higher than that of among Europeans (N = 40, 40%; P =
0.0007). Patients with intestinal schistosomiasis (S. mansoni)
presentedwith symptoms in 57%of cases (323/570). Chronic
symptomswere seen amongnon-Europeans in 14% (49/348),
among expatriates in 7% (9/131), and among Europeans in
9% of cases (8/91). Spleno- and/or hepatomegaly were re-
ported in 14 patients, two of whom were Europeans traveling
as tourists, four expatriates, and eight non-Europeans.
Diagnosis of schistosomiasis. Direct pathogen detection
was reported in 43.4% of cases (635/1,465). Rates among
non-Europeans (55.5%) were higher than among Europeans
(24.7%) and expatriates (43.3%). A positive serologic test was
used for diagnosis in 29.3% of cases (430/1,465) and antigen
testing was used in 5.4% of cases (79/1,465). Use of PCR
(sample type not reported) for diagnosis was reported in one
case.
Asymptomatic patients (N = 623) were diagnosed via mi-
croscopy in 47.4% of cases (295/623) and in 39% of cases
(243/623) via serology or antigen testing. Asymptomatic non-
Europeans were more often diagnosed via microscopy in
62.4%of cases (179/287) thanwith serology or antigen testing
(29.3%, 84/287). Likewise, the majority of asymptomatic ex-
patriates had positive microscopy in 52.1% (75/144). In con-
trast, asymptomatic Europeans received the diagnosis more
often via serology or antigen testing in 57.8% of cases
(111/192) than with microscopy, which was positive in 21.3%
of cases (41/192).
Treatment and hospitalization of travelers with
schistosomiasis. Of 1,465 patients, 15.7% (230/1,465) were
hospitalized due to schistosomiasis. Duration of hospitaliza-
tion ranged from1 to 90 days (median: 5 days). Of hospitalized
cases, 63.4% (N = 146) were attributable to S. mansoni and
19.1% (N = 44) to S. haematobium. Among hospitalized
S. mansoni patients, 65% presented with acute symptoms
or abdominal pain. In contrast, hospitalized patients with
S. haematobium infection presented with acute symptoms in
only 34%of cases but in 59%with chronic symptoms such as
hematuria.
TABLE 3
Region of infection by patient type
Region of infection Total European Expatriate Non-European
Africa, not further definition 15 (1%) 9 (0.6%) 4 (0.3%) 2 (0.1%)
Africa, Central 245 (16.7%) 21 (1.4%) 92 (6.3%) 132 (9%)
Africa, East 490 (33.4%) 261 (17.8%) 82 (5.6%) 147 (10%)
Africa, Northern 59 (4%) 10 (0.7%) 1 (< 0.1%) 48 (3.3%)
Africa, Southern 15 (1%) 9 (0.6%) 5 (0.3%) 1 (< 0.1%)
Africa, Western 581 (40%) 144 (10%) 41 (3%) 396 (27%)
America, Central* 2 (0.1%) 2 (0.1%) 0 0
America, South 21 (1.4%) 8 (0.6%) 1 (< 0.1%) 12 (0.8%)
Asia, East 2 (0.1%) 1 (< 0.1%) 1 (< 0.1%) 0
Asia, South 4 (0.2%) 2 (0.1%) 0 2 (0.1%)
Asia, Southeast 21 (1.4%) 13 (0.9%) 3 (0.2%) 5 (0.3%)
Asia, West 7 (0.5%) 3 (0.2%) 1 (< 0.1%) 3 (0.2%)
Caribbean 2 (0.1%) 2 (0.1%) 0 0
Unknown 1 (< 0.1%) 1 (< 0.1%) 0 0
* Information as given by travellers. Since Schistosomiasis is not endemic in Central America, the infection may have been acquired in other countries visited before.
FIGURE 1. Geographical distribution of all reported schistosomiasis infections by patient type: (A) European patients, (B) expatriate patients, and
(C) non-European patients; gray scale in percent of all infections on the African continent among each patient group.
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Praziquantel was used in all patients for whom treatment
data were available (N = 1385); glucocorticoids were used
in 21 patients. No deaths due to schistosomiasis were
reported.
DISCUSSION
This TropNet study examined patients presenting with
schistosomiasis after leaving schistosomiasis-endemic
countries either because of travel or migration to Europe. This
study is the largest database of human schistosomiasis cases
outside endemic areas to date, providing detailed data on
epidemiology and clinical features of patients with schisto-
somiasis. This analysis includes and analyzes the complete
dataset of schistosomiasis patients from 1997 to 2010
recorded by TropNet. Parts of this data were published earlier
as sentinel data (1999–2001) and as a preliminary report only
for the year 2007.12,13
Consistent with other studies,14,15 travelers andmigrants in
our study were young with an overall median age of 29. In-
terestingly, European travelerswith schistosomiasis appear to
be younger than the average short-term traveler population
and travelers diagnosed with other infections. Median ages
among other large traveler populations to Africa were found to
range between 36 and 39 years.8,9 Younger patients may ei-
ther be less informed or more willing to accept the risk of
infection by swimming in freshwater. Another consistent ob-
servation in comparison to other studies14,15 is that men are
almost twice as likely to be affected as women, regardless of
the type of travel.
Not surprisingly, pretravel advice was obtained only by a
minority of travelers. Rates among expatriates were however
unexpectedly low, as these individuals usually receive a pre-
travel consultation. European travelers showed the highest
rateof pretravel consultations, although itwasobtainedonly in
41%of cases. This is below reported ratesof over 50%among
short-term travelers in the 2010 EuroTravNet Study, which
included returning travelers and migrants in Europe.8 In-
terestingly, only 2% (4/177) of non-European VFR travelers
diagnosed with schistosomiasis obtained pretravel advice.
This rate is also lower than the reported rate of 25% among
VFRs in the 2010 study.8 Furthermore, another study in-
vestigating returning VFRs showed a pretravel advice rate of
16% among non-European VFRs.16
Positive associations of pretravel advice were previously
shown to improve presentation rates within 6 months re-
gardless of symptoms in schistosomiasis patients.14 A finding
whichwe confirm in our data, as pre-travel advice led to higher
presentation rates within the first 3 months after return. It is
evident that rates of pretravel consultation among all patient
groups are unsatisfactory and efforts need to be intensified to
counsel all travelers on risks and prevention of schistosomi-
asis infection, in particular among VFR travelers.
In line with previous reports,14,15,17–19 most cases (95%) of
schistosomiasis were acquired on the African continent. Our
study provides detailed information on regional distribution of
schistosomiasis infections among travelers and migrants
adding valuable information to previous studies,14,15 which
provided epidemiological data with differentiation of the schis-
tosomiasis species but less specification on the traveler type.
The high numbers of infections among Europeans in East
Africamost likely reflects frequent travel to thedeveloped tourist
infrastructure in this region.Swimming in freshwatersof theEast
African great lakes area including Lake Malawi or Lake Victoria
remains very attractive to tourists, especially since some
local touroperatorsdenya riskof schistosomiasis transmission.
The risk of acquiring schistosomiasis may also be taken de-
liberately.20 InWestAfrica, theDogoncounty inMali is a popular
tourist destination and is another focus for schistosomiasis in-
fections among travelers as reported by several other outbreak
FIGURE 2. Infections due to Schistosoma haematobium on the Af-
rican continent. Geographical distribution of all S. haematobium in-
fections; color scale in percent of N = 318 infections. This figure
appears in color at www.ajtmh.org.
FIGURE 3. Infections due to Schistosoma mansoni on the African
continent. Geographical distribution of allS.mansoni infections; color
scale in percent of N = 570 infections. This figure appears in color at
www.ajtmh.org.
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reports and case series. Furthermore, clusters of cases often
are reported among groups of travelers to these regions.21–23
Visser and others described the type of schistosomiasis patient
to Mali as “uninformed and inexperienced” or “the more ad-
venturous traveller.”21 The west African tourist in our study
obtained pretravel advice with lower probability contrast to
tourists visiting East Africa (P = 0.009).
High numbers of infections among expatriates in our study
imply that they take the risk of swimming in freshwater despite
knowing the risk of infection. In line with our data, volunteers
and aid workers were shown to have a 2-fold higher risk for
schistosomiasis comparedwith other travellers.14 Expatriates
tend to adopt local habits and have repeated exposures.
Young children of expatriates are particularly at risk of ac-
quiring continuous reinfection.1,24
Fifty seven and a half percent of patients presented with
symptoms, whereas 42.5% of patients were asymptomatic or
without reported symptoms. Previous studies in similar pop-
ulations report rates of asymptomatic patients between 36%
and 50%.14,15,19 Many asymptomatic patients are diagnosed
when attending aposttravelmedical checkup.Other individuals
may be worried about an infection acquired in the tropics and
present to travel clinics regardless of symptoms.19 Thus, the
number of unreported cases or undiagnosed cases may even
be higher. A recent small study for example suggests a large
reservoir of untreated schistosomiasis among immigrants from
endemic countries.25 We show high rates of asymptomatic
presentation (62%) among expatriates indicating that medical
consultations after returning from assignments in tropical
countries are useful for detection of asymptomatic schistoso-
miasis.Whittyandotherspointout that targeted laboratory tests
including blood count, serology plus microscopy yield good
detection rates in asymptomatic travellers.19 Our data show
high detection rates via microscopy among asymptomatic pa-
tients, especially in patients originating fromendemic regions or
long-term visitors. Among European short-term travellers, se-
rology more often led to diagnosis, indicating a low parasitic
burden in travelers after a single exposure.
Presentation of symptomatic patients differed between the
patient groups. Europeans presented more likely because
of fever and musculoskeletal symptoms. Previous studies
likewise describe fever as the major symptom of acute
schistosomiasis.14,17,18 Fatigueorgeneral tiredness reported in
earlier studies15,19 as a major symptom in up to 26% of cases
was however less frequent in our study population (9%). Clin-
ical presentation of non-Europeans occurred more often be-
causeof symptoms indicative for chronic schistosomiasis such
as hematuria, bloody diarrhea, or weight loss.
Microscopy and serology remain the central diagnostic
methods in schistosomiasis.1,26 Forty-three percent were
diagnosed via microscopy, which is in line with other re-
ports (22–45%).15,17–19 Five percent of cases were di-
agnosed via antigen testing and PCR was only used in one
patient. Recently published studies demonstrate high
TABLE 4
Symptoms by patient type
Acute symptoms among all cases of schistosomiasis (all species N = 1,465)








N = 748 Pearson χ2 test
Fever 175 (12%) 101 (21%) 22 (10%) 52 (7%) P < 0.0001
Skin symptoms 99 (7%) 46 (9%) 7 (3%) 46 (6%) P = 0.0037
Respiratory symptoms 61 (4%) 37 (8%) 10 (4%) 14 (2%) P < 0.0001
Musculoskeletal symptoms 77 (5%) 46 (9%) 6 (3%) 25 (3%) P < 0.0001
Headache 79 (5%) 34 (7%) 10 (4%) 35 (5%) P = 0.15
Fatigue 129 (9%) 51 (10%) 29 (13%) 49 (7%) P = 0.005
Vomiting 32 (2%) 9 (2%) 1 (< 1%) 22 (3%) P = 0.024†, P = 0.26‡,
P = 0.18§
Diarrhea 148 (10%) 67 (14%) 18 (8%) 63 (8%) P = 0.0042
Abdominal pain 131 (9%) 27 (6%) 9 (4%) 95 (13%) P < 0.0001
Neurological symptoms 20 (1%) 5 (1%) 5 (2%) 10 (1%) P = 0.4
All acute/subacute symptoms
(as defined earlier)
391 (27%) 167 (34%) 53 (23%) 171 (23%) P < 0.0001









N = 203 Pearson χ2 test
Chronic/urogenital symptoms 166 (52%) 40 (40%) 3 (20%) 123 (61%) *P = 0.0026†, P = 0.0009‡,
P = 0.16§









N = 348 Pearson χ2 test
Overall chronic symptoms 66 (12%) 8 (9%) 9 (7%) 49 (14%) P = 0.059
Hepato-/splenomegaly 14 (2%) 2 (2%) 4 (3%) 8 (2%) P = 0.74†, P = 1‡,
P = 1§
Hematochezia, melena 9 (1.6%) 2 (2%) 0 7 (2%) statistical testing not
relevant/significant
Weight loss 18 (3%) 0 0 18 (5%) statistical testing not
relevant/significant
* Fisher’s exact test applied.
† Expatriate versus non-European.
‡ European versus non-European.
§ Expatriate versus European.
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sensitivity and specificity for PCR.26 Furthermore, this
method can be used for pathogen detection in serum, feces
and urine.27,28 This method may be highly suitable for di-
agnosing patients with acute as well as chronic infec-
tions.26 Other approaches such as high sensitive antigen
assays have equally shown promising results.6,26 If PCR as
a routinemethod is not available, a combination of full blood
count, serology, and microscopy of stool and urine yields
best diagnostic results.19
The retrospective study design has inherent limitations.
First, bias could have occurred by themethod of passive case
finding, resulting in a relevant number of cases with no
schistosomiasis species information. Second, a bias toward
symptomatic individuals as well as patients with severe
symptoms presenting to referral centers for tropical medicine
must be assumed. Likewise, a bias due to different reporting
practices and a potential preference in reporting of confirmed
versus suspected cases could have occurred. Only one di-
agnostic method was reportable in the questionnaire, al-
though several methods may have been used.
In conclusion, schistosomiasis remains a relevant infection
in travelers and migrants to Europe. Most infections in Euro-
peans occur in travelers visiting a small number of countries in
west and east Africa. These travelers should be counseled
intensively on the risk of schistosomiasis infection. Given the
generally low rate of pretravel advice in all patient groups and
its effectiveness in prevention of infection, the coverage of
pretravel advice should be extended. Well-informed patients
present faster to a travel clinic in case of symptoms. Swim-
ming in freshwater was however not prevented by pretravel
advice. Posttravel consultations particularly for returning ex-
patriates are useful, given the high potential of microscopy
and serology for detecting asymptomatic infections demon-
strated in this report.
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Infectious Diseases Unit, Hospital General Universitario de Elche, Ali-
cante, Spain, E-mail: jramosrincon@yahoo.es. Gudrun Just-Nübling,
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